Who is sponsoring NCT05952089?

NCT05952089 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT05952089?

Interventions in NCT05952089: Danicamtiv, Midazolam.

What condition does NCT05952089 study?

NCT05952089 studies Heart Failure With Reduced Ejection Fraction.

Is NCT05952089 still recruiting?

NCT05952089 is currently completed. Last updated 4 April 2024.

Last reviewed 2024-04-04 · How we verify

NCT05952089

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure

Completed Phase 1 Last updated 4 April 2024

What this trial tests

Phase 1 trial testing Danicamtiv in Heart Failure With Reduced Ejection Fraction in 13 participants. Completed in 19 March 2024.

Timeline

17 August 2023

Primary endpoint
15 March 2024

19 March 2024

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	17 August 2023
Primary completion	15 March 2024
Estimated completion	19 March 2024
Sites	5 locations across United States

Drugs / interventions tested

Danicamtiv — full drug profile →
Midazolam (midazolam) — full drug profile →

Conditions studied

Heart Failure With Reduced Ejection Fraction — all drugs for Heart Failure With Reduced Ejection Fraction →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

Adults 18 to 75, any sex, with Heart Failure With Reduced Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Differential effects of myosin activators on myocardial contractile function in nonfailing and failing human hearts.
Choi J, Wood PT, Holmes JB, Dominic KL, et al · · 2025 · cited 6× · PMID 39453428 · DOI 10.1152/ajpheart.00252.2024

Verify or expand the search:

Other trials of Danicamtiv

Trials testing the same drug.

NCT06027437 — A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Health · Phase 1 · completed
NCT05806359 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participan · Phase 1 · completed
NCT05162222 — A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Hea · Phase 1 · completed

Other recruiting trials for Heart Failure With Reduced Ejection Fraction

Currently open trials in the same condition.

NCT07465653 — A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction · Phase 1 · recruiting
NCT07465679 — A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treat · active not recruiting
NCT07275931 — Digital Support Program for Patients With Heart Failure - a Cluster-Randomized Hybrid Type 2 Study · NA · recruiting
NCT06942221 — Digital Solutions in Heart Therapy (DIGNITY) · NA · recruiting
NCT07087613 — Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG · recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05952089 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 4 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05952089.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing